Regen BioPharma, Inc.'s CEO Discusses and Clarifies the Potential of the NR2F6 Activator Program

Source: Regen BioPharma, Inc. Press Release

Regen BioPharma, Inc., (OTCQB: RGBP and OTCQB: RGBPP) recently announced that it has identified small molecules that activate the Company's newly identified immune checkpoint, NR2F6.  This is the first of a series of steps in developing small molecules which the Company plans to use as a basis for creating an oral drug that may have potent anti-inflammatory properties.

"In autoimmune diseases the immune system, for unknown reasons, is highly active against normal tissue.  The activators we have identified should interfere with this autoimmune process.  The production of some of the key molecules that activate the immune system are controlled by NR2F6.  In experiments which will be performed in the near future, we expect our compounds to stop production of these immune-activating molecules," said Harry Lander, Ph.D., President and Chief Scientific Officer of Regen.

See full press release